Patents by Inventor William Glen Holloway

William Glen Holloway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AHR AGONISTS
    Publication number: 20230127797
    Abstract: The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
    Type: Application
    Filed: September 13, 2022
    Publication date: April 27, 2023
    Inventors: Cheryl Ann CARSON, Christian Alexander CLARKE, Douglas Linn GERNERT, Steven James GREEN, William Glen HOLLOWAY
  • [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes
    Patent number: 11401274
    Abstract: The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE inhibitor.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 2, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, William Glen Holloway, Cynthia Darshini Jesudason, Qing Shi
  • IL-17A INHIBITORS
    Publication number: 20220073526
    Abstract: The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis.
    Type: Application
    Filed: January 3, 2020
    Publication date: March 10, 2022
    Inventors: David Andrew Coates, Kwame Frimpong, William Glen Holloway, Brian Spencer Jones, Adam Marc Levinson, Charles Willis Lugar, III, Michael Enrico Richett, Brian Morgan Watson, Michael Edward Woodman
  • [1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives
    Patent number: 11180503
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 23, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES
    Publication number: 20210147437
    Abstract: The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE inhibitor.
    Type: Application
    Filed: August 3, 2018
    Publication date: May 20, 2021
    Inventors: Michael James Genin, William Glen Holloway, Cynthia Darshini Jesudason, Qing Shi
  • [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-6(5H)-ONE DERIVATIVES
    Publication number: 20200123154
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Application
    Filed: July 26, 2018
    Publication date: April 23, 2020
    Applicant: Eli Lilly and Company
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • 1,2-BENZOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISORDERS
    Publication number: 20170246166
    Abstract: The present invention provides 1,2-benzothiazole compounds particularly useful in the treatment of diabetic nephropathy and other chronic kidney disorders and other diabetic complications.
    Type: Application
    Filed: November 13, 2015
    Publication date: August 31, 2017
    Inventors: Michael James Genin, I, William Glen Holloway, Mark David Rekhter
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080269296
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z. A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 30, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080255152
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 16, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charies Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • Diaryl ethers as opioid receptor antagonist
    Patent number: 7381719
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: June 3, 2008
    Assignee: Eli Lilly and Company
    Inventors: Maria-Jesus Blanco-Pillado, Marta Garcia De La Torre, Nuria Diaz Buezo, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi